All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The BCL6 degrader BI-3802 works by inducing polymerization of its target protein, which in turn triggers the addition of ubiquitin tags on the polymerized structure and degradation by the proteasome, scientists reported in the Nov. 18, 2020, issue of Nature.
By transplanting a plant-specific degradation pathway controlled by a phytohormone, auxin, into non-plant cells, researchers at the Japanese National Institutes of Genetics have developed a rapid protein degradation process – the auxin-inducible degron (AID) technology.
The industry's expanding quest for protein degraders grew a little larger on July 9 with Sanofi SA tapping Kymera Therapeutics Inc. to advance two new protein degrader programs, one of which will target IRAK4 in patients with immune-inflammatory diseases and another for an undisclosed target. Each program could yield multiple therapies.
BOSTON – At the AACR-NCI-EORTC Molecular Targets meeting in October, speakers in the second plenary session gave examples both of how far protein degradation has come as a pharmacological approach, and how far it could still go.
